ADVERTISEMENT
ADVERTISEMENT

Evidence is mounting that psychedelic drugs can help treat diseases. Here are the most promising uses

There's been a resurgence of interest in psychedelic drugs' potential to treat conditions like depression. Research is beginning to lead to new treatments.

  • There's been a recent resurgence of interest in
  • That research is beginning to lead to the development of
  • Illicit drugs like

Once portrayed as illegal ways to "drop out" or "tune in," psychedelic and semi-psychedelic drugs like psilocybin and ecstasy are finally starting to turn into federally-regulated medicines.

The tide began to turn over the summer, when a little-known startup backed by Silicon Valley tech mogul Peter Thiel churned out enough of the active ingredient in magic mushrooms to send 20,000 people on a psychedelic trip. It was part of a larger research effort by the company, called Compass Pathways, to study how psychedelic drugs could be used to treat depression.

It was only the beginning. Earlier this month, a German entrepreneur launched a new company called Atai Life Sciences with $25 million to back more studies that explore the therapeutic potential of psychedelic drugs on psychiatric disease. And last week, federal regulators deemed psilocybin worthy of "breakthrough status," a designation designed to speed the drug approval process for treatments that serve unmet needs.

ADVERTISEMENT

MDMA, better known as ecstasy, nabbed that designation last year. Just this week, researchers published a new study that suggested MDMA could help people dealing with post-traumatic stress disorder (PTSD).

Prior to the recent wave of research, the study of psychedelic substances — many of which remain officially recognized as Schedule 1 drugs with no legal medical use — was nearly impossible. But in recent years, the efforts have begun to make headway.

The obvious psychedelic suspects aren't the only drugs in the realm that are turning into medicines. The first prescription drug made with marijuana, which many experts consider a psychedelic in high enough doses, was green-lit by U.S. federal regulators in June.

On Monday, researchers published the latest findings of a year-long study designed to assess if MDMA could play a role in treatment for PTSD. Their positive findings suggest that it could.

ADVERTISEMENT

After the treatment, in which

the treatment was tied to some unpleasant side effects including insomnia, tiredness, and headaches. The drug, which can be dangerous when used without medical supervision because it raises body temperature and blood pressure.

MDMA also recently received a key federal designation designed to hasten the research and approval process. Some experts believe the drug will be approved as early as 2021.

Researchers studying psilocybin, the main psychoactive ingredient in hallucinogenic mushrooms, have likened its quick effects on cancer patients to a "surgical intervention" for depression.

ADVERTISEMENT

Brain scan studies suggest that depression ramps up the activity in brain circuits linked with negative emotions, and weakens the activity in circuits linked with positive ones. Psilocybin appears to restore balance to that system.

Two for-profit companies are currently leading the research in the space. The first, called Compass Pathways, is backed by entrepreneur Peter Thiel and has plans to start its own clinical trials of magic mushrooms for depression later this year. The second, a biotech startup launched last month called Atai, is focused on financing more of the kind of research that Compass is doing. Atai has already raised $25 million from investors like ex-hedge fund manager Mike Novogratz and Icelandic entrepreneur Thor Bjorgolfsson.

Some researchers have high hopes that a psilocybin-inspired drug will get approved within a decade. David Nutt, director of the neuropsychopharmacology unit at Imperial College London, told Business Insider last year that he believed psilocybin would become an "accepted treatment" for depression before 2027.

The first prescription drug made from marijuana won federal approval this summer.

ADVERTISEMENT

Called Epidiolex, the drug is designed to treat two rare forms of childhood epilepsy using a cannabis compound called cannabidiol (or CBD).

British-based GW Pharmaceuticals makes the drug. It does not contain THC, the well-known psychoactive component of marijuana responsible for the drug's characteristic high.

The federal thumbs-up comes on the heels of several months of promising research results and a positive preliminary vote from the Food and Drug Administration this spring. Experts are hopeful that the approval will unleash a wave of new interest in the potential medical applications of CBD and other marijuana compounds to treat other psychiatric and neurological diseases.

A widely used anesthetic that is also known as a party drug, ketamine was shown to have benefits as a rapid-fire antidepressant nearly a decade ago. Early studies suggested ketamine could help people who failed to respond to existing medications or were suicidal.

ADVERTISEMENT

The authors of one paper called ketamine "the most important discovery in half a century."

As opposed to existing antidepressants, ketamine acts on a brain mechanism that scientists have only recently begun to explore. Homing in on this channel appears to provide relief from depression that is better, arrives faster, and works in far more people than current drugs.

After a lack of new drugs for depression spurred scientists to go back to the drawing board, pharmaceutical companies like Allergan and Johnson & Johnson are now in hot pursuit of new blockbuster depression drugs that take after ketamine.

Allergan's drug is in the last phase of clinical trials and has received a key FDA designation designed to speed it through the approval process. A Johnson & Johnson spokesperson told Business Insider that it expects to file for FDA approval of its drug — a nasal spray made with the chemical mirror image of ketamine — this year, despite what some experts have called disappointing results from a study done in its most recent phase of research.

ADVERTISEMENT
  • Why psychedelics like magic mushrooms kill the ego and fundamentally transform the brain
  • The DEA's surprising shift on marijuana could keep a booming $1 billion industry in check, experts say
  • Stanford researchers are learning how ketamine fights depression — and why the drug's called 'the most important discovery in half a century

JOIN OUR PULSE COMMUNITY!

Unblock notifications in browser settings.
ADVERTISEMENT

Eyewitness? Submit your stories now via social or:

Email: eyewitness@pulse.ng

Recommended articles

Here's everything to know about being a virgin on your wedding night

Here's everything to know about being a virgin on your wedding night

7 do's and don’ts of the Holy month of Ramadan

7 do's and don’ts of the Holy month of Ramadan

Top 5 sweetest celebrity mother-child relationships that stand out for us

Top 5 sweetest celebrity mother-child relationships that stand out for us

International Women's Day: 5 Nigerian female celebrities championing women’s rights

International Women's Day: 5 Nigerian female celebrities championing women’s rights

Top 5 female directors in Nollywood

Top 5 female directors in Nollywood

6 things that will break a Muslim's fast during Ramadan

6 things that will break a Muslim's fast during Ramadan

5 benefits of fasting during Ramadan

5 benefits of fasting during Ramadan

5 reasons Easter was more fun when we were children

5 reasons Easter was more fun when we were children

Dos and don’ts of supporting Muslims during Ramadan

Dos and don’ts of supporting Muslims during Ramadan

ADVERTISEMENT
ADVERTISEMENT